Karyopharm Therapeutics Inc. (KPTI)
NASDAQ: KPTI · Real-Time Price · USD
0.687
+0.027 (4.06%)
At close: Jan 21, 2025, 4:00 PM
0.700
+0.013 (1.91%)
After-hours: Jan 21, 2025, 6:32 PM EST
Karyopharm Therapeutics Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for KPTI stock have an average target of 5.00, with a low estimate of 3.00 and a high estimate of 7.00. The average target predicts an increase of 627.91% from the current stock price of 0.69.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for KPTI stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | +919.07% | Jan 15, 2025 |
| Piper Sandler | Piper Sandler | Buy Maintains $4 → $5 | Buy | Maintains | $4 → $5 | +627.91% | Nov 6, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | +919.07% | Nov 6, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | +919.07% | Nov 1, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | +919.07% | Aug 7, 2024 |
Financial Forecast
Revenue This Year
154.02M
from 146.03M
Increased by 5.47%
Revenue Next Year
163.77M
from 154.02M
Increased by 6.33%
EPS This Year
-0.64
from -1.25
EPS Next Year
-0.73
from -0.64
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 162.8M | 204.8M | 234.0M | |||
| Avg | 154.0M | 163.8M | 198.8M | |||
| Low | 141.8M | 128.3M | 152.7M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 11.5% | 33.0% | 42.9% | |||
| Avg | 5.5% | 6.3% | 21.4% | |||
| Low | -2.9% | -16.7% | -6.8% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -0.63 | -0.44 | -0.32 | |||
| Avg | -0.64 | -0.73 | -0.46 | |||
| Low | -0.64 | -1.04 | -0.63 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.